Oramed Pharmaceuticals (ORMP) Times Interest Earned (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Times Interest Earned came in at -$23.16 in Q1 2026, up 94.85% YoY from -$11.88 in Q1 2025, and up 49.78% on a QoQ basis from -$46.11 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Times Interest Earned (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of Times Interest Earned data on file, last reported at -$23.16 in Q1 2026.
- Quarterly Times Interest Earned rose 94.85% year-over-year to -$23.16 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$90.17 (up 93.7% YoY) and the FY2025 annual result came in at -$63.39, down 17815.86% from the prior year.
- Times Interest Earned climbed to -$23.16 in Q1 2026, from -$46.11 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $1.75 in Q4 2024 to a low of -$520.8 in Q1 2023.
- A 5-year average of -$75.41 and a median of -$11.92 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned soared 233.23% — and 2025, when it slumped 8893.92%.
- Tracing ORMP's Times Interest Earned over 5 years: stood at -$141.68 in 2022, then surged by 99.07% to -$1.32 in 2023, then soared by 233.23% to $1.75 in 2024, then sank by 2730.86% to -$46.11 in 2025, then jumped by 49.78% to -$23.16 in 2026.
- The last three Times Interest Earned figures came in at -$23.16 (Q1 2026), -$46.11 (Q4 2025), and -$18.11 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.30 |
| Mar 31, 2026 | -23.16 |
| Dec 31, 2025 | -46.11 |
| Sep 30, 2025 | -18.11 |
| Jun 30, 2025 | -18.57 |
| Mar 31, 2025 | -450.00 |
| Dec 31, 2024 | 1.75 |
| Sep 30, 2024 | -6.94 |
| Jun 30, 2024 | -12.01 |
| Mar 31, 2024 | -5.00 |
| Dec 31, 2023 | -1.32 |
| Sep 30, 2023 | -3.50 |
| Jun 30, 2023 | -4.99 |
| Mar 31, 2023 | -520.80 |
| Dec 31, 2022 | -141.68 |
| Sep 30, 2022 | -8.61 |
| Jun 30, 2022 | -11.02 |
| Mar 31, 2022 | -11.92 |
| Aug 31, 2021 | -3,027.88 |
| Nov 30, 2019 | -121.45 |